8-K: Merit Medical Pivots WRAPSODY US Commercial Strategy

Merit Medical Systems, Inc. announced a strategic pivot for its WRAPSODY Cell-Impermeable Endoprosthesis U.S. commercialization after CMS deferred its TPT incremental payment application.

Summary

• The U.S. Centers for Medicare & Medicaid Services (CMS) deferred Merit Medical's application for Transitional Pass-Through (TPT) incremental payment for WRAPSODY Cell-Impermeable Endoprosthesis (CIE) procedures in outpatient and ambulatory surgery center (ASC) settings.
• The earliest possible effective date for TPT incremental payment is now January 1, 2027.
• Merit has elected to withdraw its TPT application and will immediately begin full U.S. commercialization of the WRAPSODY CIE.
• The company maintains its full-year 2025 U.S. revenue forecast for WRAPSODY CIE sales in the range of $2 million to $4 million.
• The WRAPSODY CIE has strong clinical evidence, including remarkable 24-month efficacy results from both the randomized arteriovenous fistula arm and single-arm arteriovenous graft cohort of the WRAPSODY WAVE Trial.

Sentiment

Score: 5

Explanation: The deferral of TPT payment by CMS is a significant setback, pushing potential incremental reimbursement out by two years. However, Merit Medical's immediate strategic pivot to full commercialization, coupled with strong clinical data and maintained 2025 revenue guidance for the product, suggests a proactive approach to mitigate the negative impact and confidence in the product's underlying value.

Positives

• Merit Medical will immediately begin full U.S. commercialization of the WRAPSODY CIE, aiming to increase patient access and optimize adoption.
• The WRAPSODY CIE is supported by strong clinical evidence, including remarkable 24-month efficacy results from the WRAPSODY WAVE Trial, which serves as a key differentiator against competitors.
• Management believes the new commercial strategy will improve patient outcomes, reduce treatment costs for a large and growing patient population, and generate strong, margin-accretive revenue growth.
• The company is maintaining its full-year 2025 U.S. revenue forecast for WRAPSODY CIE sales between $2 million and $4 million, indicating confidence in near-term sales despite the CMS deferral.

Negatives

• The U.S. Centers for Medicare & Medicaid Services (CMS) deferred Merit Medical's application for Transitional Pass-Through (TPT) incremental payment for WRAPSODY CIE procedures.
• The earliest possible effective date for TPT incremental payment is now January 1, 2027, delaying potential incremental reimbursement for two years.
• The deferral of the TPT application initially impacted the pace of U.S. commercialization efforts for the WRAPSODY CIE.

Risks

• Forward-looking statements are subject to risks and uncertainties, as described in Merit's filings with the U.S. Securities and Exchange Commission (SEC), including Part I, Item 1A, Risk Factors in its Annual Report on Form 10-K for the year ended December 31, 2024, and updated in its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025.
• Actual results may differ, and may differ materially, from anticipated results.

Future Outlook

Merit Medical expects its new commercial strategy for WRAPSODY CIE to improve patient outcomes, reduce treatment costs for a large and growing patient population, and generate strong, margin-accretive revenue growth in the coming years. The company believes it is well-positioned to penetrate the U.S. dialysis access maintenance market opportunity.

Management Comments

• "While we are disappointed with the deferral of our application for TPT incremental payment, we believe this presents an opportunity for an important strategic pivot." Martha G. Aronson, President and CEO.
• "Our efforts to secure incremental payment in the outpatient and ASC settings have impacted the pace of U.S. commercialization of our innovative solution for physicians treating hemodialysis patients suffering from venous outflow obstructions." Martha G. Aronson, President and CEO.
• "We are enacting a new commercial strategy that increases patient access and optimizes adoption and utilization of our clinically superior technology. We expect this strategy to improve patient outcomes, reduce the cost of treating this large and growing patient population, and generate strong, margin-accretive revenue growth for Merit in the years to come." Martha G. Aronson, President and CEO.
• "We have elected to withdraw our application for TPT incremental payment and intend to begin our full commercialization of the WRAPSODY CIE in the U.S. immediately." Martha G. Aronson, President and CEO.
• "The clinical evidence supporting this device is remarkable, particularly the recently announced 24-month efficacy results from both the randomized arteriovenous fistula arm and single-arm arteriovenous graft cohort of our WRAPSODY WAVE Trial." Martha G. Aronson, President and CEO.
• "This impressive clinical data represents not only an invaluable tool in our discussions with physicians, hospital administrators, and payers, but also is a key differentiator versus existing competitors." Martha G. Aronson, President and CEO.
• "Armed with the best technology, the strongest clinical evidence, and a focused and engaged commercial team, we believe we are well positioned to penetrate the U.S. dialysis access maintenance market opportunity in the coming years." Martha G. Aronson, President and CEO.

Industry Context

The announcement relates to the U.S. dialysis access maintenance market, specifically for treating venous outflow obstructions in hemodialysis patients. The WRAPSODY CIE aims to restore vascular access, a critical need in this patient population. The company highlights its clinical data as a "key differentiator versus existing competitors," indicating a competitive landscape where clinical efficacy is paramount for market penetration. The deferral of TPT payment by CMS underscores the significant role of reimbursement policies in the commercial success of medical devices in the U.S. healthcare system.

Comparison to Industry Standards

• The WRAPSODY CIE's 24-month efficacy results from the WRAPSODY WAVE Trial (randomized arteriovenous fistula arm and single-arm arteriovenous graft cohort) are described as "remarkable" and a "key differentiator versus existing competitors" in the dialysis access maintenance market. While specific competitor names or their results are not provided in the filing, the strong clinical data positions WRAPSODY CIE favorably against current solutions for venous outflow obstructions.

Stakeholder Impact

• Shareholders: Potential for delayed revenue growth from TPT payments, but mitigated by immediate full commercialization and expected margin-accretive revenue growth from the new strategy. Continued 2025 revenue forecast provides some stability.
• Patients: Increased access to WRAPSODY CIE in the U.S. due to the new commercial strategy, potentially leading to improved outcomes for hemodialysis patients with venous outflow obstructions.
• Physicians/Hospital Administrators/Payers: Strong clinical data provides an invaluable tool for discussions, potentially influencing adoption despite the lack of immediate TPT payment.
• Employees: The strategic pivot and focus on full commercialization may impact sales and marketing teams, requiring adaptation to the new strategy.

Next Steps

• Begin full commercialization of the WRAPSODY CIE in the U.S. immediately.
• Continue evaluating real-world clinical outcomes of WRAPSODY CIE in the WRAP North America Registry (designed to enroll up to 250 patients).
• Continue evaluating real-world outcomes of WRAPSODY CIE in the WRAP Global Registry.

Key Dates

Recommendation

The deferral of the TPT payment is a negative development, as it delays a significant reimbursement pathway for the WRAPSODY CIE by two years. This could impact the initial ramp-up and profitability of the product. However, Merit Medical's swift strategic pivot to full commercialization, coupled with the strong clinical evidence for WRAPSODY CIE and the maintenance of the 2025 revenue forecast, suggests the company is confident in its ability to drive adoption through other means. The long-term potential of the product remains, but the immediate reimbursement challenge introduces uncertainty. A "hold" recommendation allows investors to observe the effectiveness of the new commercial strategy and its impact on revenue growth and market penetration without overreacting to the reimbursement delay.

Keywords

Merit Medical, MMSI, WRAPSODY, Endoprosthesis, CMS, Reimbursement, Medical Device, Dialysis Access, Vascular Access, Healthcare Technology, FDA Approval, Commercialization